CDKN2A and head and neck squamous cell carcinoma: According to our study, when we analyzed OPSCC subgroup (29 patients) in our HNSCC cohort, the results showed superior treatment outcome of OS (HR 0.845, 95%CI 0.307-2.330; p=0.745), DFS (HR 0.735, 95%CI 0.275-1.966; p=0.539), and LRFS (HR 0.278, 95%CI 0.032-2.392; p=0.244) of p16-positive over p16-negative OPSCC patients.